Biotech firm Attovia Therapeutics secures $289M in its expanded IPO, pricing 17M shares at $17 each.
Attovia Therapeutics priced its upsized initial public offering at $17 per share, raising approximately $289M in gross proceeds. The company sold 17M shares in the offering, which was larger than initially planned.
The biotech firm focuses on developing next-generation biotherapeutics for immune-mediated diseases using its proprietary ATTOBODY platform. Its lead candidate, ATTO-1310, targets chronic pruritic conditions, though the pipeline remains in early-stage development.
Proceeds will fund clinical trials and further platform expansion, with no immediate market reaction reported.